Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 25, 2026, 8:24 am
Author: Getaka|Social: XLinkedIn

IOL Chemicals & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 25, 2026, 8:24 am

Market Cap 2,109 Cr.
Current Price 71.9
Intrinsic Value₹46.74
High / Low 127/57.5
Stock P/E16.9
Book Value 59.7
Dividend Yield1.39 %
ROCE8.86 %
ROE6.13 %
Face Value 2.00
PEG Ratio-2.47

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for IOL Chemicals & Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 121 Cr. 96.0 137/84.325.0 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.15 Cr. 1.65 3.69/1.60 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,470 Cr. 318 479/20872.6 24.30.21 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 28.7 Cr. 38.6 79.8/37.2 10.10.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 93.0 Cr. 63.5 64.5/17.0372 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,117.38 Cr1,097.9156.24201.320.37%16.29%15.20%6.10

All Competitor Stocks of IOL Chemicals & Pharmaceuticals Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 541523587563545520504502526523528552568
Expenses 510480491490481476454452484476465490510
Operating Profit 32439673644450514247636257
OPM % 6%8%16%13%12%9%10%10%8%9%12%11%10%
Other Income 5797788764577
Interest 4554443244443
Depreciation 11121214161616171819192020
Profit before tax 22338862513238392628454641
Tax % 28%27%25%25%26%28%25%24%26%26%30%25%26%
Net Profit 16246546382328301921323430
EPS in Rs 0.530.822.221.571.290.790.961.010.650.701.081.161.02

Last Updated: January 1, 2026, 6:16 am

Below is a detailed analysis of the quarterly data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 568.00 Cr.. The value appears strong and on an upward trend. It has increased from 552.00 Cr. (Jun 2025) to 568.00 Cr., marking an increase of 16.00 Cr..
  • For Expenses, as of Sep 2025, the value is 510.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 490.00 Cr. (Jun 2025) to 510.00 Cr., marking an increase of 20.00 Cr..
  • For Operating Profit, as of Sep 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 62.00 Cr. (Jun 2025) to 57.00 Cr., marking a decrease of 5.00 Cr..
  • For OPM %, as of Sep 2025, the value is 10.00%. The value appears to be declining and may need further review. It has decreased from 11.00% (Jun 2025) to 10.00%, marking a decrease of 1.00%.
  • For Other Income, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 7.00 Cr..
  • For Interest, as of Sep 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.00 Cr. (Jun 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
  • For Depreciation, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00 Cr..
  • For Profit before tax, as of Sep 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Jun 2025) to 41.00 Cr., marking a decrease of 5.00 Cr..
  • For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
  • For Net Profit, as of Sep 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 34.00 Cr. (Jun 2025) to 30.00 Cr., marking a decrease of 4.00 Cr..
  • For EPS in Rs, as of Sep 2025, the value is 1.02. The value appears to be declining and may need further review. It has decreased from 1.16 (Jun 2025) to 1.02, marking a decrease of 0.14.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 2:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5643855807119831,6851,8941,9672,1842,2172,1332,0792,227
Expenses 4683735296088631,2761,3211,3751,9271,9901,9011,8771,988
Operating Profit 961151102120410574592257227232202239
OPM % 17%3%9%14%12%24%30%30%12%10%11%10%11%
Other Income 111161016241725302213
Interest 605961686451216816161515
Depreciation 32293030303236394346637278
Profit before tax 5-75-39631336533571223189183138159
Tax % 35%-12%4%21%12%30%32%22%26%26%26%27%
Net Profit 3-67-40528237361445166140135101116
EPS in Rs 0.23-2.80-1.420.170.998.3212.7015.155.644.774.613.443.96
Dividend Payout % 0%0%0%0%0%0%5%8%14%17%22%23%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-2333.33%40.30%112.50%460.00%746.43%52.32%23.27%-62.70%-15.66%-3.57%-25.19%
Change in YoY Net Profit Growth (%)0.00%2373.63%72.20%347.50%286.43%-694.11%-29.05%-85.97%47.03%12.09%-21.61%

IOL Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:18%
5 Years:2%
3 Years:-2%
TTM:3%
Compounded Profit Growth
10 Years:13%
5 Years:-22%
3 Years:-17%
TTM:-11%
Stock Price CAGR
10 Years:21%
5 Years:-8%
3 Years:10%
1 Year:4%
Return on Equity
10 Years:18%
5 Years:14%
3 Years:8%
Last Year:6%

Last Updated: September 5, 2025, 7:50 am

Balance Sheet

Last Updated: December 10, 2025, 2:52 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 29485656565757595959595959
Reserves 1601601291321604177571,2021,3321,4481,5531,6291,692
Borrowings 377400453447422284593448033117159
Other Liabilities 17594135182214184297347526434600577503
Total Liabilities 7417027728178529421,1701,6101,9602,0212,2442,3822,413
Fixed Assets 4114034003744064124695125617519331,1701,142
CWIP 3344217271948105901012264
Investments 00000001220212121
Other Assets 2972953694224395036821,0481,2921,1591,1901,1681,185
Total Assets 7417027728178529421,1701,6101,9602,0212,2442,3822,413

Below is a detailed analysis of the balance sheet data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 59.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 59.00 Cr..
  • For Reserves, as of Sep 2025, the value is 1,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,629.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 63.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 117.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 42.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 503.00 Cr.. The value appears to be improving (decreasing). It has decreased from 577.00 Cr. (Mar 2025) to 503.00 Cr., marking a decrease of 74.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 2,413.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 1,142.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,170.00 Cr. (Mar 2025) to 1,142.00 Cr., marking a decrease of 28.00 Cr..
  • For CWIP, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 42.00 Cr..
  • For Investments, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 1,185.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,168.00 Cr. (Mar 2025) to 1,185.00 Cr., marking an increase of 17.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 2,413.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..

Notably, the Reserves (1,692.00 Cr.) exceed the Borrowings (159.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 78-47188312027347138091123290179
Cash from Investing Activity + -12-5-27-23-50-63-184-317-121-119-191-154
Cash from Financing Activity + -66509-60-70-197-272-58-2-4-9246
Net Cash Flow 1-2-01-113154-31-0770

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-281.00-389.00-402.00-345.00-302.00126.00515.00589.00213.00147.00199.0085.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 323155585443525679838190
Inventory Days 190279201201109666498957711195
Days Payable 11992102115834262799574123112
Cash Conversion Cycle 1032181541448067557479866973
Working Capital Days -55939362343466671727158
ROCE %11%-3%4%12%15%56%68%54%18%14%12%9%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 48.19%48.19%48.19%48.19%48.19%48.19%48.19%52.62%52.62%52.62%52.62%52.62%
FIIs 2.43%3.54%2.33%2.18%1.40%1.39%1.63%1.49%1.47%2.59%2.25%2.08%
DIIs 0.23%0.25%0.35%0.36%0.29%0.09%0.07%0.08%0.07%0.02%0.05%0.03%
Public 49.15%48.02%49.12%49.27%50.11%50.34%50.11%45.81%45.84%44.76%45.10%45.26%
No. of Shareholders 1,40,1771,26,0041,35,3971,34,2351,30,0031,28,6891,25,9791,26,7011,30,0021,25,0401,36,1291,33,531

Shareholding Pattern Chart

No. of Shareholders

IOL Chemicals & Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal Nifty Microcap 250 Index Fund 25,342 0.2 1.1525,3422025-04-22 17:25:300%
Motilal Oswal S&P BSE Healthcare ETF 243 0.12 0.012432025-04-22 17:25:300%
Groww Nifty Total Market Index Fund 65 0.01 0652025-04-22 17:25:300%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22
FaceValue 2.0010.0010.0010.00
Basic EPS (Rs.) 3.4422.9023.7028.56
Diluted EPS (Rs.) 3.4422.9023.7028.56
Cash EPS (Rs.) 5.9033.6131.5635.93
Book Value[Excl.RevalReserv]/Share (Rs.) 57.49274.49256.81237.15
Book Value[Incl.RevalReserv]/Share (Rs.) 57.49274.49256.81237.15
Revenue From Operations / Share (Rs.) 70.83363.27377.64372.00
PBDIT / Share (Rs.) 7.6544.4042.8049.45
PBIT / Share (Rs.) 5.2033.6834.9442.08
PBT / Share (Rs.) 4.7030.9432.1338.30
Net Profit / Share (Rs.) 3.4422.9023.7028.56
NP After MI And SOA / Share (Rs.) 3.4422.9023.7028.56
PBDIT Margin (%) 10.8012.2211.3313.29
PBIT Margin (%) 7.349.279.2511.31
PBT Margin (%) 6.638.518.5010.29
Net Profit Margin (%) 4.866.306.277.67
NP After MI And SOA Margin (%) 4.866.306.277.67
Return on Networth / Equity (%) 5.988.349.2212.04
Return on Capital Employeed (%) 8.6111.7413.0917.05
Return On Assets (%) 4.245.986.888.54
Total Debt / Equity (X) 0.060.000.050.03
Asset Turnover Ratio (%) 0.890.991.110.00
Current Ratio (X) 1.892.002.022.11
Quick Ratio (X) 1.301.241.301.31
Inventory Turnover Ratio (X) 5.293.824.180.00
Dividend Payout Ratio (NP) (%) 23.2321.8316.8821.00
Dividend Payout Ratio (CP) (%) 13.5614.8712.6816.69
Earning Retention Ratio (%) 76.7778.1783.1279.00
Cash Earning Retention Ratio (%) 86.4485.1387.3283.31
Interest Coverage Ratio (X) 15.2216.1915.2635.02
Interest Coverage Ratio (Post Tax) (X) 7.859.359.4522.91
Enterprise Value (Cr.) 1705.421979.481718.711979.92
EV / Net Operating Revenue (X) 0.820.920.770.90
EV / EBITDA (X) 7.597.596.846.82
MarketCap / Net Operating Revenue (X) 0.860.990.740.95
Retention Ratios (%) 76.7678.1683.1178.99
Price / BV (X) 1.061.321.101.49
Price / Net Operating Revenue (X) 0.860.990.740.95
EarningsYield 0.050.060.080.08

After reviewing the key financial ratios for IOL Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
  • For Cash EPS (Rs.), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 33.61 (Mar 24) to 5.90, marking a decrease of 27.71.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 70.83. It has decreased from 363.27 (Mar 24) to 70.83, marking a decrease of 292.44.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 7.65. This value is within the healthy range. It has decreased from 44.40 (Mar 24) to 7.65, marking a decrease of 36.75.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 5.20. This value is within the healthy range. It has decreased from 33.68 (Mar 24) to 5.20, marking a decrease of 28.48.
  • For PBT / Share (Rs.), as of Mar 25, the value is 4.70. This value is within the healthy range. It has decreased from 30.94 (Mar 24) to 4.70, marking a decrease of 26.24.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
  • For PBDIT Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 12.22 (Mar 24) to 10.80, marking a decrease of 1.42.
  • For PBIT Margin (%), as of Mar 25, the value is 7.34. This value is below the healthy minimum of 10. It has decreased from 9.27 (Mar 24) to 7.34, marking a decrease of 1.93.
  • For PBT Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 6.63, marking a decrease of 1.88.
  • For Net Profit Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 5. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 8. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 5.98. This value is below the healthy minimum of 15. It has decreased from 8.34 (Mar 24) to 5.98, marking a decrease of 2.36.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has decreased from 11.74 (Mar 24) to 8.61, marking a decrease of 3.13.
  • For Return On Assets (%), as of Mar 25, the value is 4.24. This value is below the healthy minimum of 5. It has decreased from 5.98 (Mar 24) to 4.24, marking a decrease of 1.74.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.06, marking an increase of 0.06.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.99 (Mar 24) to 0.89, marking a decrease of 0.10.
  • For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.89, marking a decrease of 0.11.
  • For Quick Ratio (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.30, marking an increase of 0.06.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.29. This value is within the healthy range. It has increased from 3.82 (Mar 24) to 5.29, marking an increase of 1.47.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 21.83 (Mar 24) to 23.23, marking an increase of 1.40.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.56. This value is below the healthy minimum of 20. It has decreased from 14.87 (Mar 24) to 13.56, marking a decrease of 1.31.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 76.77. This value exceeds the healthy maximum of 70. It has decreased from 78.17 (Mar 24) to 76.77, marking a decrease of 1.40.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has increased from 85.13 (Mar 24) to 86.44, marking an increase of 1.31.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 15.22. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 15.22, marking a decrease of 0.97.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.85. This value is within the healthy range. It has decreased from 9.35 (Mar 24) to 7.85, marking a decrease of 1.50.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 1,705.42. It has decreased from 1,979.48 (Mar 24) to 1,705.42, marking a decrease of 274.06.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.82, marking a decrease of 0.10.
  • For EV / EBITDA (X), as of Mar 25, the value is 7.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 7.59.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
  • For Retention Ratios (%), as of Mar 25, the value is 76.76. This value exceeds the healthy maximum of 70. It has decreased from 78.16 (Mar 24) to 76.76, marking a decrease of 1.40.
  • For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.06, marking a decrease of 0.26.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
  • For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of IOL Chemicals & Pharmaceuticals Ltd as of February 25, 2026 is: ₹50.17

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 25, 2026, IOL Chemicals & Pharmaceuticals Ltd is Overvalued by 30.22% compared to the current share price ₹71.90

Intrinsic Value of IOL Chemicals & Pharmaceuticals Ltd as of February 25, 2026 is: ₹46.74

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 25, 2026, IOL Chemicals & Pharmaceuticals Ltd is Overvalued by 34.99% compared to the current share price ₹71.90

Last 5 Year EPS CAGR: -6.83%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.50%, which is a positive sign.
  2. The company has higher reserves (828.54 cr) compared to borrowings (221.38 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (248.92 cr) and profit (173.85 cr) over the years.
  1. The stock has a high average Working Capital Days of 48.25, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 100.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in IOL Chemicals & Pharmaceuticals Ltd:
    1. Net Profit Margin: 4.86%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 8.61% (Industry Average ROCE: 16.29%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 5.98% (Industry Average ROE: 15.2%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.85
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.3
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 16.9 (Industry average Stock P/E: 56.24)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

IOL Chemicals and Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 29/09/1986 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L24116PB1986PLC007030 and registration number is 007030. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 2079.21 Cr. and Equity Capital is Rs. 58.71 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsVillage & Post Office Handiaya, Barnala Punjab 148107Contact not found
Management
NamePosition Held
Mr. Rajender Mohan MallaChairman & Ind.Director
Mr. Varinder GuptaManaging Director
Mr. Vikas GuptaJoint Managing Director
Mr. Abhiraj GuptaExecutive Director
Mr. Kushal Kumar RanaDirector - Works
Mr. Harpal SinghIndependent Director
Mr. Sharad TyagiIndependent Director
Mr. Rajni JhaIndependent Director

FAQ

What is the intrinsic value of IOL Chemicals & Pharmaceuticals Ltd?

IOL Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 25 February 2026) is ₹46.74 which is 34.99% lower the current market price of ₹71.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,109 Cr. market cap, FY2025-2026 high/low of ₹127/57.5, reserves of ₹1,692 Cr, and liabilities of ₹2,413 Cr.

What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd?

The Market Cap of IOL Chemicals & Pharmaceuticals Ltd is 2,109 Cr..

What is the current Stock Price of IOL Chemicals & Pharmaceuticals Ltd as on 25 February 2026?

The current stock price of IOL Chemicals & Pharmaceuticals Ltd as on 25 February 2026 is ₹71.9.

What is the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks is ₹127/57.5.

What is the Stock P/E of IOL Chemicals & Pharmaceuticals Ltd?

The Stock P/E of IOL Chemicals & Pharmaceuticals Ltd is 16.9.

What is the Book Value of IOL Chemicals & Pharmaceuticals Ltd?

The Book Value of IOL Chemicals & Pharmaceuticals Ltd is 59.7.

What is the Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd?

The Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd is 1.39 %.

What is the ROCE of IOL Chemicals & Pharmaceuticals Ltd?

The ROCE of IOL Chemicals & Pharmaceuticals Ltd is 8.86 %.

What is the ROE of IOL Chemicals & Pharmaceuticals Ltd?

The ROE of IOL Chemicals & Pharmaceuticals Ltd is 6.13 %.

What is the Face Value of IOL Chemicals & Pharmaceuticals Ltd?

The Face Value of IOL Chemicals & Pharmaceuticals Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in IOL Chemicals & Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports